ArticleESMO gastrointestinal oncology2025
Continuous imaging to evaluate growth and drug responses of patient-derived colorectal tumouroids.
Article in ESMO gastrointestinal oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- A Classifier for Patient-Derived Colorectal Tumoroid Drug Sensitivity Using Confocal Imaging and Growth Rate Inhibition Metrics.Cancer research communications · 2026Article
Corrections and comments
- Erratum issued
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The use of patient-derived tumouroids is expected to have major implications in preclinical drug testing and clinical decision support. Data acquisition from these samples in drug screens, however, is often limited by time-consuming procedures, scarce screening material, and destructive, single-parameter endpoint measurements. Design: We seek to increase data collected from patient-derived tumouroids and here present a method for non-destructive, continuous image-based analysis of colorectal tumouroid growth and shape under chemotherapeutic perturbations, conducted within a clinically relevant timeframe. Results: We assessed several readouts automatically derived from continuous imaging data and concluded that tumouroid growth, and the effect of growth inhibiting drugs, can be robustly monitored by measuring the total tumouroid-covered area in images. We also found that measures of average tumouroid size, diameter, and perimeter provide complementary insights. Conclusions: Our tumouroid analysis method offers a strategy to maximise data extraction from non-destructive imaging techniques while preserving tumouroids for future research, all within a clinically relevant timeframe.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.